Dubai, United Arab Emirates -Sunday, January 29th 2017 [ ME NewsWire ] Newby Teas, the luxury tea company, is launching a redesigned From the Heart gift box for Valentine’s Day 2017. Followers of the world’s leading luxury tea brand – will recognise the original design, but with a dramatic twist. The box will change, but the tea will remain the popular mix of ultra-luxury varieties. With a modern take on the beautiful style of the classical Dutch Masters, the new box design builds on a legacy of award-winning packaging available from www.newbyteas.ae The new From the Heart Silken Pyramids gift box design features a twist on the classic aesthetics of the Dutch Masters, with a solitary naughty ladybird adding a touch of wit. The set comprises an assortment of four flawless green teas and tisanes, perfect for romance. Strawberry & Mango tisane is a succulent combination with a lingering light honey finish. Rooibos Orange blends the nutty flavour of the rooibos shrub, grown only in ... Read more »

• REVLIMID® is the first and only medicine granted positive CHMP opinion for post-Autologous Stem Cell Transplantation (ASCT) maintenance therapy in MM • The new indication expands the availability of REVLIMID® across the disease continuum of MM BOUDRY, Switzerland-Monday, January 30th 2017 [ ME NewsWire ] (BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of REVLIMID® as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma (MM) who have undergone autologous stem cell transplantation (ASCT). Once approved by the European Commission, REVLIMID® will be the first and only licensed maintenance treatment available to these patients. Multiple myeloma is an incurable and life-threatening blood cancer that is characterised by tumou ... Read more »

• REVLIMID® est le premier médicament à recevoir un avis favorable du CHMP pour le traitement d'entretien du myélome multiple non préalablement traité chez les patients ayant reçu une greffe autologue de cellules souches (autogreffe) • Cette nouvelle indication élargit la place de REVLIMID® dans les différentes phases de la maladie. PARIS-Lundi 30 Janvier 2017 [ ME NewsWire ] (BUSINESS WIRE)-- Celgene France, une filiale à part entière de Celgene Corporation (NASDAQ: CELG), a annoncé aujourd'hui que le Comité des médicaments à usage humain (CHMP) de l'Agence européenne du médicament (EMA) a adopté un avis favorable à l'utilisation de REVLIMID® en monothérapie pour l’entretien des patients adultes atteints de myélome multiple nouvellement diagnostiqué et ayant reçu une autogreffe. Une fois approuvé par la Commission européenne (CE), REVLIMID® sera le premier traitement d'entretien à bénéficier d'une autorisation pour ces patients. Le myélome multiple est un cancer du sang incurabl ... Read more »

AMSTERDAM-Friday, January 27th 2017 [ ME NewsWire ] (BUSINESS WIRE)-- Pershing Square Holdings, Ltd. (ticker: PSH:NA) posted today its Annual Investor Update Presentation on its website, https://www.pershingsquareholdings.com/company-reports/letters-to-shareholders/. The presentation includes a performance review, an update of the fund’s portfolio and an organizational update. About Pershing Square Holdings, Ltd. Pershing Square Holdings, Ltd. (PSH:NA) is an investment holding company structured as a closed end fund that makes concentrated investments principally in North American companies. Contacts Maitland James Devas, +44 20 7379 5151 Media-pershingsquareholdings@maitland.co.uk Permalink : http://me-newswire.net/news/3260/en